US equities |
NVDA $189.15 ▲+4.15% MU $685.50 ▲+4.43% AMD $441.00 ▲+9.05% SNDK $837.01 ▲+3.79% SPCX $131.00 ▲+5.97% TSLA $360.52 ▲+4.90% AAPL $344.87 ▲+0.20% TSM $375.71 ▲+6.40%
FinancialContent

Mobia Medical, Inc. - Common Stock (NQ:MOBI)

11.01 -0.27 (-2.39%)
Delayed Quote Updated: 10:58 AM EST, Nov 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mobia Medical, Inc. - Common Stock

News headline image
What Mobia Medical (MOBI) Said on Its Q3 Earnings Call ↗
Mobia Medical (NASDAQ:MOBI) raised its full-year revenue forecast after third-quarter sales rose 73%, driven by broader adoption of its Vivistim therapy at new and existing programs. The company... 
Via MarketBeat
Topics Earnings
Mobia Medical (NASDAQ:MOBI) Beats Q3 Revenue but Wider Loss and Slowing Growth Guidance Pressure Shares ↗
Via Chartmill
News headline image
Mobia Medical Reports Third Quarter 2026 Financial Results
From Mobia Medical, Inc.
Via GlobeNewswire
News headline image
Mobia Medical to Participate in the 8th Annual Wolfe Research Healthcare Conference
From Mobia Medical, Inc.
Via GlobeNewswire
News headline image
Mobia Medical to Report Third Quarter 2026 Financial Results on November 5, 2026
From Mobia Medical, Inc.
Via GlobeNewswire
News headline image
Mobia Medical Announces Addition of Paired VNS to Updated AHA Stroke Guidelines
From Mobia Medical, Inc.
Via GlobeNewswire
News headline image
Mobia Medical (MOBI) Q2 2026 Earnings Call Transcript ↗
Revenue doubled as Vivistim unit sales and active territories expanded. 
Via The Motley Fool
Topics Earnings World Trade
News headline image
Mobia Medical Q2 Earnings Call Highlights ↗
Mobia Medical (NASDAQ:MOBI) reported second-quarter revenue of $13.5 million, up 102% from $6.7 million a year earlier, as adoption of its Vivistim paired vagus nerve stimulation therapy expanded... 
Via MarketBeat
Topics Earnings
News headline image
Mobia Medical Reports Second Quarter 2026 Financial Results
From Mobia Medical, Inc.
Via GlobeNewswire
News headline image
Mobia Medical Appoints Myriam Curet, M.D., to its Board of Directors
From Mobia Medical, Inc.
Via GlobeNewswire
News headline image
Mobia Medical to Report Second Quarter 2026 Financial Results on August 11, 2026
From Mobia Medical, Inc.
Via GlobeNewswire
News headline image
Mobia Medical Appoints Reza Zadno, Ph.D., to its Board of Directors
From Mobia Medical, Inc.
Via GlobeNewswire
News headline image
Mobia Medical Announces Publication of Two-Year Data from VNS-REHAB Trial Demonstrating Durable and Continued Stroke Recovery with Vivistim® Paired VNS™ Therapy
Findings published in Neurology® show improvements in upper-limb motor function, activities of daily living, and quality of life were sustained for at least two years 
From Mobia Medical, Inc.
Via GlobeNewswire
News headline image
Mobia Medical Announces Vivistim® Procedure Remains Assigned to New Technology APC 1580 under CMS Proposed 2027 Hospital Outpatient Prospective Payment System Rule
From Mobia Medical, Inc.
Via GlobeNewswire